Old Web
English
Sign In
Acemap
>
authorDetail
>
N. Lamontagne
N. Lamontagne
Cystic fibrosis
Pathology
Mutation
Medicine
f508del cftr
3
Papers
3
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
EPS3.02 Exploratory immune assays distinguish healthy volunteer from CF patient cohorts and were validated in a dose escalation study of QR-010 in subjects with cystic fibrosis homozygous for the F508del CFTR mutation
2018
Journal of Cystic Fibrosis
S. Noël
T. Leal
K. Obieglo
D. Nijholt
N. Lamontagne
S Montgomery
M.V. Bujny
Show All
Source
Cite
Save
Citations (0)
40 QR-010 via inhalation is safe, well-tolerated, and achieves systemic concentrations in a single ascending dose study in subjects with cystic fibrosis homozygous for the F508del CFTR mutation
2017
Journal of Cystic Fibrosis
P. Drevinek
N. Pready
N. Lamontagne
S Montgomery
N. Henig
Show All
Source
Cite
Save
Citations (1)
WS13.1 QR-010, an investigational RNA therapeutic, improves CFTR activity in cystic fibrosis subjects homozygous for the F508del mutation
2017
Journal of Cystic Fibrosis
Steven M. Rowe
Isabelle Sermet-Gaudelus
John P. Clancy
Dave P Nichols
Jerry A. Nick
K. De Boeck
George M. Solomon
J.S. Elborn
M.A. Mall
James Bolognese
F. Bouisset
W. den Hollander
N. Lamontagne
N. Tomkinson
Noreen R Henig
Show All
Source
Cite
Save
Citations (2)
1
map